Glaxo Rises to Highest Since 2002 on FDA Panel Backing

GlaxoSmithKline Plc rose to the highest price in 11 years after advisers to the U.S. Food and Drug Administration recommended that experimental treatment Breo Ellipta be approved to treat a lung disorder.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.